Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026764 (
multiple myeloma
)
36,148
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The transcription factor PU.1 is essential for myeloid and B-cell development. Down-regulation of PU.1 by disruption of its 14-kb 5' upstream regulatory element induced acute myeloid leukemia, T-cell lymphoma, and chronic lymphocytic leukemia-like disease in murine models. In the present study, we found that PU.1 was down-regulated in the majority of human
myeloma
cell lines and a subset of freshly isolated
myeloma
cells, in contrast to relatively high expression of PU.1 in normal plasma cells. Patients in this low PU.1 expression subset may have a poor prognosis. In human
myeloma
cell lines, the 17-kb 5' upstream enhancer and the promoter region of the PU.1 gene were highly methylated, and this is consistent with disappearance of
DNase I
-hypersensitive sites in these regions. To elucidate the significance of down-regulation of PU.1, we generated stable
myeloma
cell lines with an inducible PU.1 expression system. Exogenous expression of PU.1 in PU.1 null
myeloma
cell lines, U266 and KMS12PE, induced complete growth arrest and cell death. Up-regulation of PU.1 by 5-aza-2'-deoxycytidine also induced growth arrest of KMS12PE and KHM11
myeloma
cells. These data suggest that down-regulation of PU.1 is an essential step for the survival of a subset of
myeloma
cells and that up-regulation of PU.1 by demethylation agents or other types of agents may represent a new therapeutic strategy for treatment of
multiple myeloma
patients.
...
PMID:Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. 1754 13
<< Previous
1
2